Chromocell Therapeutics Corp

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Chromocell Therapeutics Corp. is a clinical-stage biotech company that engages in the development and commercialization of new therapeutics to alleviate pain. Its clinical focus is to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. The company was founded on March 19, 2021 and is headquartered in Freehold, NJ.

FREEHOLD, N.J., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that Frank Knuettel, CEO, will present live at the Life Sciences Investor Forum, hosted by VirtualInvestorConferences.com, on September 19th 2024.

Chromocell to Participate in Life Sciences Investor Forum September 19th

FREEHOLD, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that its board of directors (the “Board of Directors”) has authorized a stock repurchase plan (the “Repurchase Plan”) of up to $250,000 of Chromocell's common stock (“Common Stock”), which represents approximately 23% of the non-affiliate float based on the closing price of the Company's Common Stock as of August 6, 2024. The Repurchase Plan does not obligate the Company to acquire any particular amount of Common Stock, and it may be modified, extended or terminated by the Board of Directors at any time.

Chromocell Announces Stock Repurchase Plan

Live webcast with Frank Knuettel II, Chief Executive Officer and Chief Financial Officer, on Thursday, July 18th at 12:00 PM ET Live webcast with Frank Knuettel II, Chief Executive Officer and Chief Financial Officer, on Thursday, July 18th at 12:00 PM ET

Chromocell to Participate in the Virtual Investor Lunch Break Series

FREEHOLD, N.J., May 13, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that its CEO Frank Knuettel, will be presenting at Alliance Global Partners Healthcare Company Showcase on Tuesday, May 21, 2024.

Chromocell To Present at Alliance Global Partner's Healthcare Company Showcase on Tuesday, May 21, 2024

FREEHOLD, N.J., April 09, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that its Chief Executive Officer, Frank Knuettel, has issued the following letter to stockholders:

Chromocell Issues Letter to Stockholders from Chief Executive Officer

FREEHOLD, N.J., March 21, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corp. (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that it has formally launched its eye pain treatment program with the hiring of Dr. Simon Chandler.

Chromocell Announces Formal Launch of Eye Pain Treatment Program and Hiring of Dr. Simon Chandler

FREEHOLD, N.J., March 18, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corp. (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that its interim CEO Frank Knuettel, has been appointed as the Company's permanent CEO.

Chromocell Names Frank Knuettel as Chief Executive Officer, Removing Interim Status Held Since July 2023

AUSTIN, Texas, March 11, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corp. (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced Frank Knuettel, CEO, will present and host one-on-one meetings with investors at the Sidoti March Virtual Investor Conference, taking place on March 13-14, 2024.

Chromocell to Present at Sidoti Virtual Investor Conference March 13-14

AUSTIN. Texas, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Benuvia Operations, LLC (“Benuvia”), a leader in pharmaceutical innovation, and Chromocell Therapeutics Corp. (“Chromocell”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, are pleased to announce Chromocell's first Development and License Agreement (“Agreement”). Under the Agreement, Chromocell licensed sublingual formulation of a Diclofenac spray for the treatment of acute pain, a Rizatriptan intranasal spray formulation and an Ondansetron sublingual spray formulation, diversifying our pipeline of non-opioid pain treatment therapies, while adding therapeutic options for related conditions. This collaboration leverages the unique strengths of both organizations to enhance patient outcomes and address unmet medical needs.

Benuvia Operations, LLC and Chromocell Therapeutics Corp. Announce Strategic Partnership to Advance Healthcare Solutions

FREEHOLD, N.J., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (NYSE American: CHRO) (“Chromocell”, “our”, “us” or the “Company”), a clinical-stage biotech company focused on developing and commercializing new, non-opioid therapeutics to alleviate pain, today announced the closing of its initial public offering of 1,100,000 shares of its common stock at a public offering price of $6.00 per share. The gross proceeds from the offering to Chromocell, before deducting the underwriting discounts and estimated offering expenses, were approximately $6.6 million. Chromocell's common stock is listed on the NYSE American LLC under the ticker symbol “CHRO”.

Chromocell Therapeutics Announces Closing of Initial Public Offering for Gross Proceeds of $6.6 Million

Red Cat Holdings

Unusual Machines Inc /US

Wetouch Technology Inc

Two nano-caps debuted this past week, neither of which are included in our IPO stats. Two issuers submitted initial filings this past week, both currently listed on the OTC.

U.S. IPO Weekly Recap: Nano-Caps Debut In Quiet Week

FREEHOLD, N.J., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (NYSE American: CHRO) (“Chromocell” or the “Company”), a clinical-stage biotech company focused on developing and commercializing new, non-opioid therapeutics to alleviate pain, today announced the pricing of its initial public offering of 1,100,000 shares of common stock at a public offering price of $6.00 per share. The offering raised aggregate gross proceeds of approximately $6.6 million, prior to deducting underwriting discounts and other offering expenses.

Chromocell Therapeutics Announces Pricing of Upsized $6.6 Initial Public Offering

Chromocell Therapeutics Corporation has filed for an $8.7 million IPO to develop its treatment for chronic pain conditions. The company's lead compound is being prepared for a Phase 2a study for erythromelalgia patients with a genetic component.

IPO Update: Chromocell Therapeutics Seeks $8.7 Million In Micro-IPO

Chromocell Therapeutics has filed to raise funding from a U.S. IPO. The firm is developing a drug candidate for the treatment of the chronic nerve pain erythromelalgia.

Chromocell Therapeutics Seeks IPO For Erythromelalgia Treatment

News for Chromocell Therapeutics Corp Stock (CHRO)